Prospects brightening for EU EPP patients as Scenesse rollout looms

Summer has been slow to arrive in Europe this year, a blessing for patients with erythropoietic protoporphyria, an extreme sensitivity to sunlight, who have been awaiting the market rollout of the first approved treatment, Scenesse.